The certification is based on an inspection of the company’s Plant III facility carried out from April 22, 2026, to April 27, 2026. This certification verifies that the facility meets the Good Manufacturing Practice standards outlined in the EC Directive.
Aditi Panandikar, Managing Director of Indoco Remedies Ltd, stated, “Receiving the EU GMP certification for our formulations manufacturing plant underscores our dedication to providing high-quality products to patients worldwide.”
Also Read: Indoco Remedies shares gain over 8.5% following USFDA approval for Lacosamide oral solutionFourth Quarter Results
The pharmaceutical firm reported a net loss of ₹22 crore for the fourth quarter, an improvement from a loss of ₹40 crore in the same period last year. Revenue for the quarter increased by 22% year-on-year, rising to ₹476 crore from ₹390 crore previously.
Operationally, the company achieved an EBITDA of ₹50.2 crore, marking a significant recovery from an EBITDA loss of ₹1 crore in the corresponding quarter last year. The EBITDA margin was reported at 10.6%, demonstrating enhanced operating leverage and improved business performance across key segments.
For the entire financial year FY26, the company reported revenue of ₹1,633.5 crore, compared to ₹1,494.8 crore in the previous year. The EBITDA margin for the year rose to 9.6%, with EBITDA reaching ₹157.2 crore as opposed to ₹128 crore in the previous financial year.
Also Read: Indoco Remedies approves ₹110-crore slump sale of ophthalmic business to Sunways India
The board has proposed a dividend of ₹0.20 per equity share of face value ₹2 for FY26, pending shareholder approval at the upcoming annual general meeting.
On Wednesday (May 27), Indoco Remedies Ltd shares closed at ₹202.90, up by ₹9.05, or 4.67%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
